@article{e2dc61da493d4b8581c7dbb7fd472385,
title = "Personalised advanced therapies in parkinson{\textquoteright}s disease: The role of non-motor symptoms profile",
abstract = "Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson{\textquoteright}s disease (PD). Currently, selection of device-aided therapies is mainly focused on patients{\textquoteright} motor profile while non-motor symptoms play a role limited to being regarded as possible exclusion criteria in the decision-making process for the delivery and sustenance of a successful treatment. Differential beneficial effects on specific non-motor symptoms of the currently available device-aided therapies for PD are emerging and these could hold relevant clinical implications. In this viewpoint, we suggest that specific non-motor symptoms could be used as an additional anchor to motor symptoms and not merely as exclusion criteria to deliver bespoke and patient-specific personalised therapy for advanced PD.",
keywords = "Apomorphine, Deep brain stimulation, Device-aided therapies, Levodopa-carbidopa intestinal gel, Non-motor symptoms, Parkinson{\textquoteright}s disease, Personalised medicine",
author = "Valentina Leta and Dafsari, {Haidar S.} and Anna Sauerbier and Vinod Metta and Nataliya Titova and Lars Timmermann and Keyoumars Ashkan and Michael Samuel and Eero Pekkonen and Per Odin and Angelo Antonini and Pablo Martinez-Martin and Miriam Parry and {Van Wamelen}, {Daniel J.} and {Ray Chaudhuri}, K.",
note = "Funding Information: Conflicts of Interest: V.L. reports grants from Parkinson{\textquoteright}s UK and honoraria for sponsored symposia from UCB, Bial, Invisio, Profile and Britannia Pharmaceuticals, outside the submitted work. H.S.D. was funded by the EU Joint Programme—Neurodegenerative Disease Research (JPND), the Prof. Klaus Thiemann Foundation in the German Society of Neurology, the Felgenhauer Foundation, the KoelnFortune program of the Medical Faculty of the University of Cologne, and has received honoraria by Boston Scientific, Medtronic and Stadapharm, outside the submitted work. A.S. is funded by the Gusyk program and the Advanced Cologne Clinician Scientist program of the Medical Faculty of the University of Cologne and has received funding from the Prof. Klaus Thiemann Foundation, outside the submitted work. L.T. received payments as a consultant for Boston Scientific, honoraria as a speaker on symposia sponsored by UCB, Desitin, Boston Scientific, AbbVIE, Novartis, GlaxoSmithKline und DIAPLAN; the institution of L.T., not L.T. personally received funding by Boston Scientific, the German Research Foundation, the German Ministry of Education and Research and the Deutsche Parkinson Vereinigung, outside the submitted work. K.A. reports educational grant and honoraria from Medtronic and Abbott, outside the submitted work. M.S. has received educational support from Medtronic (paid to the institution), Parkinson{\textquoteright}s UK (via the UK DBS network), acts as a consultant for Abbott, and received honoraria from The Movement Disorders Society, outside the submitted work. E.P. reports the following disclosures outside the submitted work: consulting neurologist for Finnish Patient Insurance Centre; Standing Member of the MDS Non-Motor Parkinson{\textquoteright}s Disease, Study Group; Consulting fees: NordicInfu Care AB, Abbvie, Zambon; Member of Advisory board: Abbvie; Lecture fees: Abbott, Abbvie, Nordic Infucare. P.O. has received honoraria for lectures and advice from AbbVie, Bial, Britannia, Kyowa, Nordic Infucare and Zambon, outside the submitted work. P.M.M. has received honoraria from National School of Public Health (ISCIII), Editorial Viguera and Takeda Pharmaceuticals for lecturing in courses; and from the International Parkinson and Movement Disorder Society (IPMDS) for management of the Program on Rating Scales, outside the submitted work. M.P. has received honoraria form AbbVie and Britannia Pharmaceuticals, outside the submitted work. D.J.v.W. received a grant, and consultancy, and speaker fees from Britannia Pharmaceuticals, speaker fees from Bial Pharmaceuticals, and consultancy fees from Invisio Pharma, outside the submitted work. K.R.C. reports advisory board for AbbVie, UCB, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia; honoraria for lectures from AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim; grants (Investigator Initiated) from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial; academic grants from EU, IMI EU, Horizon 2020, Parkinson{\textquoteright}s UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Wellcome Trust, outside the submitted work. Funding Information: DAacktanAowvalieldabgmilietyntSst:aTtehme venietw: Ns oextpaprepslsiecdab alere. those of the authors and not necessarily those of the NHS, NIHR or Department of Health. The authors acknowledge the support of the International Parkinson and Movement Disorder Society Non-Motor Parkinson{\textquoteright}s disease Study Group, the NIHR London South Clinical Research Network and the NIHR Biomedical Research Centre. The authors acknowledge Juliet Staunton for the proofreading of the manuscript. This article represents independent collaborative research performed by staff who are part funded by the NIHR Biomedical acknowledge Juliet Staunton for the proofreading of the manuscript. This article represents independent collaborative research performed by staff who are part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = aug,
doi = "10.3390/jpm11080773",
language = "English",
volume = "11",
journal = "Journal of Personalized Medicine",
issn = "2075-4426",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",
}